266 related articles for article (PubMed ID: 28270496)
1. Jab1/Csn5-Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress.
Zhou F; Pan Y; Wei Y; Zhang R; Bai G; Shen Q; Meng S; Le XF; Andreeff M; Claret FX
Clin Cancer Res; 2017 Aug; 23(15):4450-4461. PubMed ID: 28270496
[No Abstract] [Full Text] [Related]
2. Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression.
Pan Y; Wang S; Su B; Zhou F; Zhang R; Xu T; Zhang R; Leventaki V; Drakos E; Liu W; Claret FX
Oncogene; 2017 Feb; 36(8):1069-1079. PubMed ID: 27524414
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer.
Wang S; Oh DY; Leventaki V; Drakos E; Zhang R; Sahin AA; Resetkova E; Edgerton ME; Wu W; Claret FX
Cancer Lett; 2019 Nov; 465():12-23. PubMed ID: 31473252
[TBL] [Abstract][Full Text] [Related]
4. Jab1 promotes glioma cell proliferation by regulating Siah1/β-catenin pathway.
Zhu Y; Qiu Z; Zhang X; Qian F; Wang B; Wang L; Shi H; Yu R
J Neurooncol; 2017 Jan; 131(1):31-39. PubMed ID: 27640199
[TBL] [Abstract][Full Text] [Related]
5. Jab1-siRNA Induces Cell Growth Inhibition and Cell Cycle Arrest in Gall Bladder Cancer Cells via Targeting Jab1 Signalosome.
Pandey P; Siddiqui MH; Behari A; Kapoor VK; Mishra K; Sayyed U; Tiwari RK; Shekh R; Bajpai P
Anticancer Agents Med Chem; 2019; 19(16):2019-2033. PubMed ID: 31345154
[TBL] [Abstract][Full Text] [Related]
6. Hsa-miR-24-3p increases nasopharyngeal carcinoma radiosensitivity by targeting both the 3'UTR and 5'UTR of Jab1/CSN5.
Wang S; Pan Y; Zhang R; Xu T; Wu W; Zhang R; Wang C; Huang H; Calin CA; Yang H; Claret FX
Oncogene; 2016 Nov; 35(47):6096-6108. PubMed ID: 27157611
[TBL] [Abstract][Full Text] [Related]
7. Thioredoxin modulates activator protein 1 (AP-1) activity and p27Kip1 degradation through direct interaction with Jab1.
Hwang CY; Ryu YS; Chung MS; Kim KD; Park SS; Chae SK; Chae HZ; Kwon KS
Oncogene; 2004 Nov; 23(55):8868-75. PubMed ID: 15480426
[TBL] [Abstract][Full Text] [Related]
8. Jab1/Cops5: a promising target for cancer diagnosis and therapy.
Yuan C; Wang D; Liu G; Pan Y
Int J Clin Oncol; 2021 Jul; 26(7):1159-1169. PubMed ID: 34019195
[TBL] [Abstract][Full Text] [Related]
9. Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer.
Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):886-900. PubMed ID: 30282449
[TBL] [Abstract][Full Text] [Related]
10. JAB1/COPS5 is a putative oncogene that controls critical oncoproteins deregulated in prostate cancer.
Danielpour D; Purighalla S; Wang E; Zmina PM; Sarkar A; Zhou G
Biochem Biophys Res Commun; 2019 Oct; 518(2):374-380. PubMed ID: 31434609
[TBL] [Abstract][Full Text] [Related]
11. CSN5/JAB1 suppresses the WNT inhibitor DKK1 in colorectal cancer cells.
Jumpertz S; Hennes T; Asare Y; Schütz AK; Bernhagen J
Cell Signal; 2017 Jun; 34():38-46. PubMed ID: 28229932
[TBL] [Abstract][Full Text] [Related]
12. Let-7d Inhibits Growth and Metastasis in Breast Cancer by Targeting Jab1/Cops5.
Wei Y; Liu G; Wu B; Yuan Y; Pan Y
Cell Physiol Biochem; 2018; 47(5):2126-2135. PubMed ID: 29975923
[TBL] [Abstract][Full Text] [Related]
13. α5-nAChR contributes to epithelial-mesenchymal transition and metastasis by regulating Jab1/Csn5 signalling in lung cancer.
Chen X; Jia Y; Zhang Y; Zhou D; Sun H; Ma X
J Cell Mol Med; 2020 Feb; 24(4):2497-2506. PubMed ID: 31930655
[TBL] [Abstract][Full Text] [Related]
14. Elucidation of the Chemopreventive Role of Stigmasterol Against Jab1 in Gall Bladder Carcinoma.
Pandey P; Bajpai P; Siddiqui MH; Sayyed U; Tiwari R; Shekh R; Mishra K; Kapoor VK
Endocr Metab Immune Disord Drug Targets; 2019; 19(6):826-837. PubMed ID: 30727937
[TBL] [Abstract][Full Text] [Related]
15. COPS5 and LASP1 synergistically interact to downregulate 14-3-3σ expression and promote colorectal cancer progression via activating PI3K/AKT pathway.
Zhou R; Shao Z; Liu J; Zhan W; Gao Q; Pan Z; Wu L; Xu L; Ding Y; Zhao L
Int J Cancer; 2018 May; 142(9):1853-1864. PubMed ID: 29226323
[TBL] [Abstract][Full Text] [Related]
16. Jab1/Cops5 contributes to chemoresistance in breast cancer by regulating Rad51.
Liu G; Yu M; Wu B; Guo S; Huang X; Zhou F; Claret FX; Pan Y
Cell Signal; 2019 Jan; 53():39-48. PubMed ID: 30244171
[TBL] [Abstract][Full Text] [Related]
17. JAB1/CSN5 and the COP9 signalosome. A complex situation.
Chamovitz DA; Segal D
EMBO Rep; 2001 Feb; 2(2):96-101. PubMed ID: 11258719
[TBL] [Abstract][Full Text] [Related]
18. The emerging roles of Jab1/CSN5 in cancer.
Wang L; Zheng JN; Pei DS
Med Oncol; 2016 Aug; 33(8):90. PubMed ID: 27412572
[TBL] [Abstract][Full Text] [Related]
19. HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells.
Hsu MC; Chang HC; Hung WC
Endocr Relat Cancer; 2007 Sep; 14(3):655-67. PubMed ID: 17914096
[TBL] [Abstract][Full Text] [Related]
20. X-linked intellectual disability gene CUL4B targets Jab1/CSN5 for degradation and regulates bone morphogenetic protein signaling.
He F; Lu D; Jiang B; Wang Y; Liu Q; Liu Q; Shao C; Li X; Gong Y
Biochim Biophys Acta; 2013 May; 1832(5):595-605. PubMed ID: 23357576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
